ANTIBODIES AGAINST ADVANCED GLYCATION END-PRODUCTS (ANTI-AGE) DISTINGUISH PATIENTS WITH A MORE INFLAMMATORY PROFILE AND WORSE OUTCOME IN SERONEGATIVE RHEUMATOID ARTHRITIS

Abstract: OP0086
Authors: T. J. van Wesemael, et al

zum Abstract

Key content:

Roughly one third of rheumatoid arthritis (RA) patients are «seronegative», and have neither detectable ACPA or RF autoantibodies. Seronegative RA is a heterogeneous group, including both milder subgroups of RA and more difficult to treat subgroups of patients. These Dutch investigators explored the role of a novel group of autoantibodies targeting advanced glycation end-product (anti-AGE), instead of peptides.
46% of RA patients versus 30% of controls had anti-age antibodies. Interestingly, anti-AGE antibodies were found at a similar prevalence in otherwise seronegative RA patients. Anti-AGE antibodies were associated with inflammation and radiologic joint damage progression in seronegative and seropositive RA patients.

Relevance:

The glycosylation of proteins influences to a large proportion their function. It is not surprising that the immune system also develops auto-antibodies against modified glycation products. Anti-AGE antibodies do not react to a modified peptide, like for example a citrullinated protein, but to a modified glycosylation of a peptide, that may occur with oxidative stress. While these anti-AGE autoantibodies are not specific for RA, they may be useful to identify ‘seronegative’ RA patients with more severe disease outcomes..

Prof. Dr. Axel Finckh
Genf

Partner

premium
advanced
basic
starter
Cancel